Clovis Oncology

Biotech stocks continued to remain under pressure in the week ended Sept. 11, swayed by the volatility that was evident in the broader market. The week also witnessed a flurry of news flow on the coronavirus vaccine front. Even as nine vaccine makers released a pledge to put safety first,...

Shares of Clovis Oncology Inc (NASDAQ: CLVS) soared higher by more than 15 percent Monday after the U.S. Food and Drug Administration granted an accelerated approval for the company's PARP inhibitor rucaparib for the treatment of women with advanced ovarian cancer which will now be branded...

Shares of Clovis Oncology Inc (NASDAQ: CLVS) lost more than 8 percent on Friday after the company confirmed that the FDA posted briefing documents ahead of the Oncologic Drugs Advisory Committee (ODAC) meeting to discuss accelerated approval of the New Drug Application (NDA) for rociletinib. The...

Shares of Clovis Oncology Inc (NASDAQ: CLVS) plunged more than 70 percent on Monday, establishing a new multi-year low of $26.05. Shares of Clovis were initially halted early Monday morning as the company reported that the FDA submitted a request for additional information on the company...

Ahead of the May 29 American Society of Clinical Oncology (ASCO) conference, analysts at Goldman Sachs reviewed the outlook for some of biotech's hottest names: Amgen, Inc. (NASDAQ: AMGN), Celgene Corporation (NASDAQ: CELG) and Clovis Oncology Inc (NASDAQ: CLVS). Goldman has Buy ratings on...

U.S. stocks were positive after the European Central Bank implemented steps to fight disinflation, including negative interest rates. On the home-front, initial jobless claims rose last week but that didn't stand in the way of the S&P 500 and Dow Jones indices trading at historical all-...

U.S. stocks were moderately higher as the S&P 500 continues to reach new highs. Investors found plenty of positives after the Federal Reserve released its summary of commentary on current economic conditions, also known as the “Beige Book.” “All twelve Federal Reserve...

U.S. stocks were lower with the S&P 500, Dow Jones and Nasdaq indices all ending in the red. In a lackluster trading session with little market moving move, investors are likely sitting on the sidelines until key data will be released later on this week. All eyes will be on Friday's...

U.S. stocks were mostly positive on the first trading session of June in which investors were left confused over ISM's May Manufacturing data which was revised twice. Both the S&P 500 and Dow Jones indices reached new highs. The S&P 500 index reached a new all time high of 1,925.88...

U.S. stocks declined for the second straight day after investors and traders digested disappointing earnings from retailers and economic reports were disappointing. The Dow suffered a triple-digit point loss and declined one percent after the retailer giant Wal-Mart failed to "wow" investors....

It’s not every day that a stock moves more than 100 percent in a single trading session but one biopharma name printed a double by the end of the trading day Monday. Clovis Oncology (NASDAQ: CLVS) was up 102 percent following its announcement of some favorable clinical data. First, its drug,...